DICE Therapeutics, Inc. – NASDAQ:DICE

Add to watchlist

Market closed

Open in 1 day

+2.39%

month

+36.87%

quarter

+126.11%

year

Market Cap	2.27B
Enterprise value	647.22M

P/E	-12.75
EV/Sales	N/A
EV/EBITDA	-5.39
Price/Sales	N/A
Price/Book	1.93
PEG ratio	-0.27
EPS	-2.19

Revenue	N/A
EBITDA	-102.4M
Income	-97.07M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

DICE Therapeutics, Inc. (NASDAQ:DICE): Profit margin
Sep 2022	0	-19.93M
Dec 2022	0	-22.61M
Mar 2023	0	-19.71M
Jun 2023	0	-34.81M

DICE Therapeutics, Inc. (NASDAQ:DICE): Debt to assets
Sep 2022	284994000	23.88M	8.38%
Dec 2022	593978000	26.99M	4.54%
Mar 2023	575604000	28.69M	4.99%
Jun 2023	550673000	31.61M	5.74%

DICE Therapeutics, Inc. (NASDAQ:DICE): Cash Flow
Sep 2022	-15.32M	46.83M	-8K
Dec 2022	-17.89M	105.97M	325.03M
Mar 2023	-22.43M	-337.65M	292K
Jun 2023	-28.57M	-792K	1.23M

DICE Therapeutics alternative data

DICE Therapeutics, Inc. (NASDAQ:DICE): Employee count
Aug 2023	81
Sep 2023	71
Oct 2023	71
Nov 2023	71
Dec 2023	71
Jan 2024	71
Feb 2024	71
Mar 2024	71
Apr 2024	71
May 2024	71
Jun 2024	71
Jul 2024	71

DICE Therapeutics
Hedge Funds Holdings Q4 2022

100.00% +1.26%

of DICE is owned by hedge funds

107 +29

hedge funds hold DICE stock

47.46M +10.57M

shares is hold by hedge funds

DICE hedge funds holdings changes

DICE Therapeutics
Insider Trading

DICE Therapeutics, Inc. (NASDAQ:DICE): Insider trades (number of shares)
Period	Buy	Sel
Oct 2022	1640000	0
Mar 2023	760922	12367
Apr 2023	0	16392
May 2023	0	126545
Jun 2023	0	2511621

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	22 Jun 2023	NORTHPOND VENTURES GP, LLC 10 percent owner 10 percent owner	Common Stock	1,969,368	$46.5	$91,575,612
Sale	22 Jun 2023	NORTHPOND VENTURES GP, LLC 10 percent owner 10 percent owner	Common Stock	523,503	$46.5	$24,342,890
Sale	1 Jun 2023	JACOBSEN JOHN R. officer: CSO officer: CSO	Common Stock	14,307	$30.31	$433,645
Sale	1 Jun 2023	JACOBSEN JOHN R. officer: CSO officer: CSO	Common Stock	4,443	$31.24	$138,799
Sale	5 May 2023	SCHELLER RICHARD H director	Common Stock	84,097	$38.51	$3,238,239
Sale	3 May 2023	ROBERTSON SCOTT M. officer: CFO & CBO officer: CFO & CBO	Common Stock	18,750	$36.55	$685,350
Sale	3 May 2023	TIMOTHY LU officer: CMO officer: CMO	Common Stock	10,000	$36.54	$365,400
Sale	3 May 2023	JUDICE KEVIN director, officer: CEO director, officer: CEO	Common Stock	13,698	$36.5	$499,977
Sale	18 Apr 2023	JACOBSEN JOHN R. officer: CSO officer: CSO	Common Stock	16,392	$30.08	$493,121
Sale	31 Mar 2023	JACOBSEN JOHN R. officer: CSO officer: CSO	Common Stock	773	$30	$23,190

DICE insider trading transactions

DICE Therapeutics
Executives

Insider	Age	Since	Compensation
Dr. J. Kevin Judice Ph.D. (1963) Founder, Chief Executive Officer & Director	62		$636,500
Dr. John R. Jacobsen Ph.D. (1968) Chief Scientific Officer	57		$480,130

DICE Therapeutics
Latest News

Wednesday, 9 August 2023
09:02	Lilly Completes Acquisition of DICE Therapeutics	prnewswire.com
Wednesday, 12 July 2023
15:59	Drugmakers' deal making will plow ahead despite antitrust scrutiny, analysts say	Market Watch
Wednesday, 21 June 2023
14:04	DICE Therapeutics (DICE) Up 37% on Buyout Offer from Eli Lilly	Zacks Investment Research
13:19	ETFs to Capitalize on Eli Lilly's Buyout of DICE Therapeutics	Zacks Investment Research
11:35	Eli Lilly takeover of DICE Therapeutics ‘makes strategic sense,' says broker	Proactive Investors
11:30	Is Eli Lilly's Dice Therapeutics Acquisition a Needle-Moving Event?	The Motley Fool
Tuesday, 20 June 2023
16:01	Eli Lilly's $2.4 Billion Acquisition of Dice Therapeutics: What Investors Need to Know	The Motley Fool
12:56	Shares of Eli Lilly, Dice Therapeutics Gain on Acquisition Announcement	GuruFocus
12:05	Eli Lilly Buys DICE Therapeutics for $2.4 Billion	Investopedia
12:00	Markets Fall at Midday, Pulled Lower by Energy Stocks	Investopedia
11:28	Why Shares of Dice Therapeutics Are Skyrocketing Tuesday	The Motley Fool
11:22	2 Biotech Stocks For Your June 2023 Watchlist	Stockmarketcom
10:33	Options Traders Blast Dice Therapeutics Stock After Buyout	Schaeffers Research
09:31	Why Is Dice Therapeutics (DICE) Stock Up 38% Today?	InvestorPlace
09:02	Eli Lilly sends DICE Therapeutics' shares soaring with $2.4B takeover	Proactive Investors
08:41	2 Biopharma Stocks Making Big Moves Tuesday	The Motley Fool
08:29	Eli Lilly to acquire Dice Therapeutics for $2.4 billion in autoimmune treatment push	CNBC
07:06	Eli Lilly to Buy Dice Therapeutics in $2.4 Billion Autoimmune Disease Push	Barrons
07:01	Dice Therapeutics rallies as it agrees to be bought by Lilly	Market Watch
07:00	Eli Lilly to buy Dice Therapeutics in $2.4 billion deal	Reuters
Tuesday, 23 May 2023
14:56	DICE Therapeutics psoriasis treatment has blockbuster potential, analysts say	Proactive Investors
Thursday, 23 March 2023
16:05	DICE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference	GlobeNewsWire
Wednesday, 8 February 2023
16:05	DICE Therapeutics to Participate at Upcoming Investor Conferences	GlobeNewsWire
Wednesday, 4 January 2023
16:05	DICE Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference	GlobeNewsWire
Monday, 2 January 2023
11:17	Are Medical Stocks Lagging DICE Therapeutics (DICE) This Year?	Zacks Investment Research
Friday, 16 December 2022
11:18	Is DICE Therapeutics (DICE) Stock Outpacing Its Medical Peers This Year?	Zacks Investment Research
Wednesday, 30 November 2022
11:17	Is DICE Therapeutics (DICE) Outperforming Other Medical Stocks This Year?	Zacks Investment Research
Friday, 18 November 2022
05:52	These 3 Stocks Are Crushing the Market. Wall Street Thinks They Can Soar at Least 78% Higher.	The Motley Fool
Thursday, 3 November 2022
16:05	DICE Therapeutics to Present at Upcoming Investor Conferences	GlobeNewsWire
Monday, 24 October 2022
12:47	DICE Therapeutics: Moving Things Along Nicely	Seeking Alpha

Ideas & Opinions

Seeking Alpha 17 Mar 2023

Biopharma Exposure In SVB Financial Group And Investor Strategy
Seeking Alpha 24 Jan 2023

DICE Therapeutics: Oral Drug Of Proven IL-17 Target
Seeking Alpha 24 Oct 2022

DICE Therapeutics: Moving Things Along Nicely
Seeking Alpha 19 Sep 2021

U.S. IPO Weekly Recap: The Fall IPO Market Is In Full Swing With An 11 IPO Week

Frequently Asked Questions (FAQ)

When is DICE Therapeutics's next earnings date?

Unfortunately, DICE Therapeutics's (DICE) next earnings date is currently unknown.
Does DICE Therapeutics pay dividends?

No, DICE Therapeutics does not pay dividends.
How much money does DICE Therapeutics make?

DICE Therapeutics has a market capitalization of 2.27B.
What is DICE Therapeutics's stock symbol?

DICE Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "DICE".
What is DICE Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of DICE Therapeutics?

Shares of DICE Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are DICE Therapeutics's key executives?
DICE Therapeutics's management team includes the following people:
- Dr. J. Kevin Judice Ph.D. Founder, Chief Executive Officer & Director(age: 62, pay: $636,500)
- Dr. John R. Jacobsen Ph.D. Chief Scientific Officer(age: 57, pay: $480,130)
Is DICE Therapeutics founder-led company?

Yes, DICE Therapeutics is a company led by its founder Dr. J. Kevin Judice Ph.D..
How many employees does DICE Therapeutics have?

As Jul 2024, DICE Therapeutics employs 71 workers.
When DICE Therapeutics went public?

DICE Therapeutics, Inc. is publicly traded company for more then 3 years since IPO on 15 Sep 2021.
What is DICE Therapeutics's official website?

The official website for DICE Therapeutics is dicemolecules.com.
Where are DICE Therapeutics's headquarters?

DICE Therapeutics is headquartered at 279 East Grand Avenue, South San Francisco, CA.
How can i contact DICE Therapeutics?

DICE Therapeutics's mailing address is 279 East Grand Avenue, South San Francisco, CA and company can be reached via phone at +65 05661402.

DICE Therapeutics, Inc.

dicemolecules.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

+65 05661402

279 East Grand Avenue
South San Francisco, CA 94080

CIK: 0001645569
ISIN: US23345J1043
CUSIP: 23345J104